271 related articles for article (PubMed ID: 21378205)
1. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
2. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Teft WA; Mansell SE; Kim RB
Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
[TBL] [Abstract][Full Text] [Related]
3. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
[TBL] [Abstract][Full Text] [Related]
4. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
Cho YA; Lee W; Choi JS
Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
[TBL] [Abstract][Full Text] [Related]
6. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
Li C; Kim M; Choi H; Choi J
Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
8. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.
Kirschbaum KM; Uhr M; Holthoewer D; Namendorf C; Pietrzik C; Hiemke C; Schmitt U
Neuropharmacology; 2010 Nov; 59(6):474-9. PubMed ID: 20599439
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
Piao Y; Shin SC; Choi JS
Biopharm Drug Dispos; 2008 May; 29(4):245-9. PubMed ID: 18338336
[TBL] [Abstract][Full Text] [Related]
12. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
13. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
Arellano C; Allal B; Goubaa A; Roché H; Chatelut E
J Pharm Biomed Anal; 2014 Nov; 100():254-261. PubMed ID: 25173109
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2017 Jun; 120():43-50. PubMed ID: 28288939
[TBL] [Abstract][Full Text] [Related]
15. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride.
Geyer J; Gavrilova O; Petzinger E
Drug Metab Dispos; 2009 Jul; 37(7):1371-4. PubMed ID: 19389858
[TBL] [Abstract][Full Text] [Related]
16. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
18. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
Shin SC; Choi JS; Li X
Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418
[TBL] [Abstract][Full Text] [Related]
19. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
20. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
